The Los Angeles-based biotech firm confirmed it has addressed all clinical, regulatory, and manufacturing feedback following its End-of-Phase 2 meeting with the FDA. Alongside these regulatory steps, the company completed four engineering runs at its in-house cGMP manufacturing facility. These efforts are intended to prepare the supply chain for the production of clinical trial materials required for the upcoming study.
In section Releases
Armata Pharmaceuticals Clears Regulatory Hurdles for AP-SA02 Phase 3 Study
Armata Pharmaceuticals has finalized its regulatory submissions to the U.S. Food and Drug Administration, clearing a path for a pivotal Phase 3 superiority study of its AP-SA02 bacteriophage candidate. The company expects to launch the trial in the second half of 2026 to treat complicated S. aureus bacteremia.
Financial backing for these preparations includes a recent $2.5 million injection from the U.S. Department of Defense, bringing the total funding under the current award to $28.7 million. CEO Dr. Deborah Birx stated that advancing the AP-SA02 program remains the company's primary objective. In conjunction with these clinical developments, Armata announced the promotion of David House to Chief Financial Officer, tasking him with overseeing the financial strategy as the company shifts toward late-stage development.
Comments (0)
No comments yet. Be the first!